PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1

Sign On

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2007 - Hormone Replacement Therapy
View All Articles in Issue

Abstract:

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, U.S. Food and Drug Administration, regulation, regulatory, unapproved drugs, FDA, compliance policy guide, legislation, Drug Efficacy Study Implementation, DESI

Related Categories: LEGAL

Printer-Friendly Version

Download in electronic PDF format for $35

Title (Click for Abstract / Details)	Author	Issue	Page	View/Buy

Related Articles from IJPC
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1	Allen Loyd V Jr	Jul/Aug 2007	350-351	Buy
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines	Allen Loyd V Jr	Jul/Aug 2016	351	View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs	Allen Loyd V Jr	Sep/Oct 2017	356	Buy
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 2	Allen Loyd V Jr	Sep/Oct 2007	438-439	Buy
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs	Allen Loyd V Jr	Nov/Dec 2015	487-488	Buy
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances	Miller David G	Jul/Aug 2015	303-305	Buy
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List")	Allen Loyd V Jr, Ashworth Lisa D	Jan/Feb 2005	44-46	Buy
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1	Allen Loyd V Jr	Sep/Oct 2015	389-390	Buy
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies	Yoch Doug	Mar/Apr 2017	95-102	Buy
Documentation: Records and Reports	Akers Michael J	Sep/Oct 2017	373-380	Buy